A phase I/II trial of the oral selective AXL inhibitor bemcentinib (BGB324) in conjunction with erlotinib in patients with advanced EGFR mutation NSCLC (NCT02424617) revealed the feasibility and well-acceptability of this combination, with benefit found in a subgroup of patients who had progressed on an EGFR inhibitor or were receiving erlotinib simultaneously in remission in the first line [87]. The gene discussed is AXL; the disease is non-small cell lung carcinoma.